Tolfenamic Acid

• Description :

  Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.

• CAS Number :

  [13710-19-5]

• Product Name Alternative :

  GEA 6414

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  COX

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/tolfenamic-acid.html

• Purity :

  99.94

• Solubility :

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

• Smiles :

  O=C(O)C1=CC=CC=C1NC2=C(C)C(Cl)=CC=C2

• Molecular Formula :

  C14H12ClNO2

• Molecular Weight :

  261.70

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Kay-Mugford P, et al. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61 (7) :802-10.|[2]Maliakal P, et al. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs. 2012 Jun;30 (3) :853-61.|[3]Sankpal UT, et al. Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells. Oncotarget. 2017 Feb 28;8 (9) :14593-14603

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  COX-2